Why the study?
Does the ACE A2350G polymorphism influence the renoprotective efficacy of renin-angiotensin inhibitors in Japanese patients with IgA nephropathy?
Does the ACE A2350G polymorphism influence the renoprotective efficacy of renin-angiotensin inhibitors in Japanese patients with IgA nephropathy?
The ACE A2350G polymorphism may serve as a genetic marker for predicting the renoprotective efficacy of renin-angiotensin inhibitors in Japanese patients with IgA nephropathy.
Should not yet guide RAS inhibitor selection in IgA nephropathy; leaves open prospective validation of genetic predictors.
The ACE A2350G polymorphism may influence responsiveness to treatments that inhibit the reninangiotensin system with respect to long term prognosis of renal function in Japanese patients with IgAN.
No takes yet. Share an insight, caveat, or question.
Ichiei Narita (2003) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: